arrow_back Back to App

Limiting Drug Costs in Medicare Program

This bill aims to limit the amounts individuals in the Medicare Part D program have to pay for their medications. Starting in 2027, monthly drug costs will not exceed the average net price of the drug or the lower cash price at the pharmacy. This is intended to reduce financial burdens for patients.
Key points
Beginning in 2027, monthly drug costs under Medicare Part D will be capped at the average net price or lower cash price.
The change is designed to lower medication expenses for low-income individuals enrolled in Medicare.
A government report is planned to assess compliance and enforcement of the new provisions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_4881
Sponsor: Rep. Malliotakis, Nicole [R-NY-11]
Process start date: 2023-07-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4881.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-07-25.

What are the main provisions?

Key points include:

  • Beginning in 2027, monthly drug costs under Medicare Part D will be capped at the average net price or lower cash price.
  • The change is designed to lower medication expenses for low-income individuals enrolled in Medicare.
  • A government report is planned to assess compliance and enforcement of the new provisions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Malliotakis, Nicole [R-NY-11].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Benefits